Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PAR-25-153
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.395 Cancer Treatment Research
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- Public or Indian Housing Auth.
- Small Businesses
- Other
- Non-501(c)(3) Nonprofits
- 501(c)(3) Nonprofits
- For Profit Organizations
- City/Township Governments
- Tribal Governments (Federally Recognized)
- Tribal Organizations (Not Federally Recognized)
- State Governments
- Independent School Districts
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- County Governments
- Special District Governments
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Federal Grant Opportunity, solicited by the National Cancer Institute (NCI) under the Department of Health and Human Services National Institutes of Health, seeks applications for the identification of small molecule compounds that can function as chemical probes or therapeutics for disease targets. The NOFO aims to support discovery research across four stages: assay development, high-throughput screening, hit validation, and hit-to-lead optimization. Eligible applicants include nonprofits, for-profit organizations, state/local governments, higher education institutions, small businesses, and tribal organizations. The opportunity is assigned to the Cancer Treatment Research grant program (CFDA 93.395).
The funding available through this grant opportunity is not specified. However, recent awards under the Cancer Treatment Research program have typically ranged from $200,000 to over $1 million in total costs, with project periods generally spanning 2-5 years. The research is primarily expected to be conducted at the recipient organizations' facilities across the United States.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-153-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity